Anaplastic lymphoma kinase (ALK)-mutated or epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma patients with brain metastases are primarily treated with systemic molecular therapies instead of upfront brain irradiation, especially when there are few and small lesions in the CNS. The gene discussed is ALK; the disease is lung adenocarcinoma.